Literature DB >> 33774744

Steroid treatment for the first episode of childhood nephrotic syndrome: comparison of the 8 and 12 weeks regimen using an individual patient data meta-analysis.

Anne M Schijvens1, Nynke Teeninga2, Eiske M Dorresteijn3, Steven Teerenstra4, Nicholas J Webb5,6, Michiel F Schreuder2.   

Abstract

Steroids are the cornerstone of the treatment of childhood nephrotic syndrome. The optimal duration for the first episode remains a matter of debate. The aim of this study is to determine whether the 8 weeks International Study of Kidney Disease in Children (ISKDC) regimen is equally effective as the 12 weeks steroid regimen from the German society of pediatric nephrology (Arbeitsgemeinschaft für Pädiatrische Nephrologie [APN]). An individual patient data (IPD) meta-analysis of randomized controlled trials reporting on prednisolone treatment for a first episode of childhood nephrotic syndrome was conducted. European trials aimed at investigating the ISKDC and/or APN steroid regimen were selected. The lead investigators of the selected trials were requested to provide the IPD of the specific treatment groups. Four trials included European cohorts using dosing schedules according to the regimens studied. IPD of two trials were available. A significant difference was found in time to first relapse after cessation of steroid treatment between the 8 and 12 weeks treatment group with a median time to relapse of 29 and 63 days, respectively. Moreover, relapse rate ratios during total follow-up were 51% higher for the 8 weeks regimen. Finally, younger children have a significantly lower time to first relapse and frequently relapsing nephrotic syndrome.Conclusions: The results of this IPD meta-analysis suggest that the 8 weeks steroid regimen for a first episode of steroid-sensitive nephrotic syndrome may not be equally effective as the 12 weeks steroid regimen. Moreover, this study highlights the importance of using uniform definitions to enable accurate comparison and interpretation of trial results.Trial registration: Registration number: CRD42020199244, date of registration 16-08-2020 What is Known: • Steroids are the cornerstone of the treatment of childhood nephrotic syndrome, however the optimal duration for the first episode remains a matter of debate. • Currently, the 8 weeks ISKDC protocol and 12 weeks APN protocol are among the most frequently used protocols in Europe. What is New: • The 8 weeks steroid regimen for a first episode of steroid-sensitive nephrotic syndrome may not be equally effective as the 12 weeks steroid regimen for the treatment of a first episode of nephrotic syndrome. • Younger children have a significantly shorter time to first relapse and time to frequent relapsing nephrotic syndrome.
© 2021. The Author(s).

Entities:  

Keywords:  Children; IPD meta-analysis; Nephrotic syndrome; Prednisolone

Year:  2021        PMID: 33774744     DOI: 10.1007/s00431-021-04035-w

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  22 in total

1.  Long versus standard initial prednisolone therapy in children with idiopathic nephrotic syndrome.

Authors:  S K Paul; G Muinuddin; S Jahan; A Begum; M H Rahman; M M Hossain
Journal:  Mymensingh Med J       Date:  2014-04

2.  Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome.

Authors:  Aditi Sinha; Abhijeet Saha; Manish Kumar; Sonia Sharma; Kamran Afzal; Amarjeet Mehta; Mani Kalaivani; Pankaj Hari; Arvind Bagga
Journal:  Kidney Int       Date:  2014-07-16       Impact factor: 10.612

3.  [Initial therapy of primary nephrotic syndrome in children: evaluation in a period of 18 months of two prednisone treatment schedules. Chilean Co-operative Group of Study of Nephrotic Syndrome in Children].

Authors:  C Norero; A Delucchi; E Lagos; P Rosati
Journal:  Rev Med Chil       Date:  1996-05       Impact factor: 0.553

4.  Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome.

Authors:  Nynke Teeninga; Joana E Kist-van Holthe; Nienske van Rijswijk; Nienke I de Mos; Wim C J Hop; Jack F M Wetzels; Albert J van der Heijden; Jeroen Nauta
Journal:  J Am Soc Nephrol       Date:  2013-01       Impact factor: 10.121

5.  Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK.

Authors:  P A McKinney; R G Feltbower; J T Brocklebank; M M Fitzpatrick
Journal:  Pediatr Nephrol       Date:  2001-12       Impact factor: 3.714

6.  Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after twelve-month follow-up: results of a three-year national surveillance study.

Authors:  William Wong
Journal:  J Paediatr Child Health       Date:  2007-05       Impact factor: 1.954

7.  Long-term outcome for children with minimal-change nephrotic syndrome.

Authors:  R S Trompeter; B W Lloyd; J Hicks; R H White; J S Cameron
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

Review 8.  Nephrotic syndrome in The Netherlands: a population-based cohort study and a review of the literature.

Authors:  Loubna El Bakkali; Robert Rodrigues Pereira; Dirk J Kuik; Johannes C F Ket; Joanna A E van Wijk
Journal:  Pediatr Nephrol       Date:  2011-05-01       Impact factor: 3.714

9.  Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation.

Authors:  Nicholas J A Webb; Rebecca L Woolley; Tosin Lambe; Emma Frew; Elizabeth A Brettell; Emma N Barsoum; Richard S Trompeter; Carole Cummins; Jonathan J Deeks; Keith Wheatley; Natalie J Ives
Journal:  BMJ       Date:  2019-05-23

10.  A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment.

Authors:  Norishige Yoshikawa; Koichi Nakanishi; Mayumi Sako; Mari S Oba; Rintaro Mori; Erika Ota; Kenji Ishikura; Hiroshi Hataya; Masataka Honda; Shuichi Ito; Yuko Shima; Hiroshi Kaito; Kandai Nozu; Hidefumi Nakamura; Takashi Igarashi; Yasuo Ohashi; Kazumoto Iijima
Journal:  Kidney Int       Date:  2014-07-23       Impact factor: 10.612

View more
  2 in total

1.  Treatment-Associated Side Effects in Patients with Steroid-Dependent Nephrotic Syndrome.

Authors:  Anca Croitoru; Mihaela Balgradean
Journal:  Maedica (Bucur)       Date:  2022-06

2.  Protocol for an open-label, single-arm, multicentre clinical study to evaluate the efficacy and safety of rituximab in the first episode of paediatric idiopathic nephrotic syndrome.

Authors:  Jialu Liu; Qian Shen; Li Xie; Jiyang Wang; Yaxuan Li; Jing Chen; Xiaoyan Fang; Xiaoshan Tang; Biyun Qian; Hong Xu
Journal:  BMJ Open       Date:  2022-10-12       Impact factor: 3.006

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.